KR101575703B1 - 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체 - Google Patents
모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체 Download PDFInfo
- Publication number
- KR101575703B1 KR101575703B1 KR1020117021833A KR20117021833A KR101575703B1 KR 101575703 B1 KR101575703 B1 KR 101575703B1 KR 1020117021833 A KR1020117021833 A KR 1020117021833A KR 20117021833 A KR20117021833 A KR 20117021833A KR 101575703 B1 KR101575703 B1 KR 101575703B1
- Authority
- KR
- South Korea
- Prior art keywords
- piperidin
- dimethyl
- oxoindolin
- methylamino
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(c(cccc1)c1N1C(CC2)CCN2C([C@](CCc2ccccc2)NC(*N(*)*)=O)=O)C1=O Chemical compound CC(C)(c(cccc1)c1N1C(CC2)CCN2C([C@](CCc2ccccc2)NC(*N(*)*)=O)=O)C1=O 0.000 description 3
- XVWBIXSBHLGBBA-UHFFFAOYSA-N CC(C)(C1)NCCN1C(C)=O Chemical compound CC(C)(C1)NCCN1C(C)=O XVWBIXSBHLGBBA-UHFFFAOYSA-N 0.000 description 1
- SUJQKAFVJRKOOT-BVAGGSTKSA-N CC(C)(c(cccc1)c1N1C(CC2)CCN2C([C@H](CCc2ccccc2)NC([C@H]2CNCCC2)=O)=O)C1=O Chemical compound CC(C)(c(cccc1)c1N1C(CC2)CCN2C([C@H](CCc2ccccc2)NC([C@H]2CNCCC2)=O)=O)C1=O SUJQKAFVJRKOOT-BVAGGSTKSA-N 0.000 description 1
- SUJQKAFVJRKOOT-ZEQKJWHPSA-N CC(C)(c1ccccc1N1C(CC2)CCN2C([C@@H](CCc2ccccc2)NC([C@H]2CNCCC2)=O)=O)C1=O Chemical compound CC(C)(c1ccccc1N1C(CC2)CCN2C([C@@H](CCc2ccccc2)NC([C@H]2CNCCC2)=O)=O)C1=O SUJQKAFVJRKOOT-ZEQKJWHPSA-N 0.000 description 1
- WDEDSODLDCECHY-SYVJQLTCSA-N CC(C)(c1ccccc1N1C(CC2)CCN2C([C@H](Cc(cc2)ccc2Cl)NC([C@@H](CC2)C[C@@H]2NC)=O)=O)C1=O Chemical compound CC(C)(c1ccccc1N1C(CC2)CCN2C([C@H](Cc(cc2)ccc2Cl)NC([C@@H](CC2)C[C@@H]2NC)=O)=O)C1=O WDEDSODLDCECHY-SYVJQLTCSA-N 0.000 description 1
- XNQXWKMOKYZEJZ-UHFFFAOYSA-N CC(CC1(CCCC1)N)=O Chemical compound CC(CC1(CCCC1)N)=O XNQXWKMOKYZEJZ-UHFFFAOYSA-N 0.000 description 1
- FNFGGSLDYLHQLO-GFCCVEGCSA-N CC(C[C@H](Cc1ccccc1)NC)=O Chemical compound CC(C[C@H](Cc1ccccc1)NC)=O FNFGGSLDYLHQLO-GFCCVEGCSA-N 0.000 description 1
- FWYIVZSBAXUFMQ-JTQLQIEISA-N CC([C@H](Cc1c(C(F)(F)F)cccc1)N)=O Chemical compound CC([C@H](Cc1c(C(F)(F)F)cccc1)N)=O FWYIVZSBAXUFMQ-JTQLQIEISA-N 0.000 description 1
- KGQLOSIUTIQZQE-JTQLQIEISA-N CC([C@H](Cc1cccc(C(F)(F)F)c1)N)=O Chemical compound CC([C@H](Cc1cccc(C(F)(F)F)c1)N)=O KGQLOSIUTIQZQE-JTQLQIEISA-N 0.000 description 1
- OHHQYEFZAUIHSB-JTQLQIEISA-N CC([C@H](Cc1ccccc1Cl)N)=O Chemical compound CC([C@H](Cc1ccccc1Cl)N)=O OHHQYEFZAUIHSB-JTQLQIEISA-N 0.000 description 1
- UFUDVDCGEMJTCA-VIFPVBQESA-N CC([C@H](Cc1ccccn1)N)=O Chemical compound CC([C@H](Cc1ccccn1)N)=O UFUDVDCGEMJTCA-VIFPVBQESA-N 0.000 description 1
- SPDOEUKTSPOJHQ-QMMMGPOBSA-N N[C@@H](Cc1ccccc1Cl)C(S)=O Chemical compound N[C@@H](Cc1ccccc1Cl)C(S)=O SPDOEUKTSPOJHQ-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20243009P | 2009-02-27 | 2009-02-27 | |
| US61/202,430 | 2009-02-27 | ||
| US28217309P | 2009-12-24 | 2009-12-24 | |
| US61/282,173 | 2009-12-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110133033A KR20110133033A (ko) | 2011-12-09 |
| KR101575703B1 true KR101575703B1 (ko) | 2015-12-10 |
Family
ID=42665356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117021833A Active KR101575703B1 (ko) | 2009-02-27 | 2010-03-01 | 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8697877B2 (enExample) |
| EP (1) | EP2401268B1 (enExample) |
| JP (1) | JP5663743B2 (enExample) |
| KR (1) | KR101575703B1 (enExample) |
| CN (1) | CN102317280B (enExample) |
| BR (1) | BRPI1007962A2 (enExample) |
| CA (1) | CA2750699C (enExample) |
| ES (1) | ES2547415T3 (enExample) |
| MX (1) | MX2011008857A (enExample) |
| RU (1) | RU2533116C2 (enExample) |
| WO (1) | WO2010098145A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013369649B2 (en) * | 2012-12-31 | 2018-07-26 | Sunovion Pharmaceuticals Inc. | Heterocyclic compounds and methods of use thereof |
| CN105849102B (zh) * | 2013-10-29 | 2020-10-16 | 生物马林药物股份有限公司 | 作为葡萄糖基神经酰胺合酶抑制剂的n-(1-羟基-3(吡咯烷基)丙烷-2-基)吡咯烷-3-甲酰胺衍生物 |
| JP6836502B2 (ja) * | 2014-05-30 | 2021-03-03 | スプハエラ ファーマ ピーヴィーティー リミテッド | 抗結核薬としての新規な化合物 |
| KR20240042400A (ko) * | 2021-07-30 | 2024-04-02 | 라퀄리아 파마 인코포레이티드 | 결정질 형태 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004529184A (ja) | 2001-05-10 | 2004-09-24 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規１−アミドメチルカルボニル−ピペリジン誘導体、該誘導体を製造するための方法及び中間体並びにこれらの化合物を含有している医薬 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW355711B (en) | 1992-11-04 | 1999-04-11 | Chugai Pharmaceutical Co Ltd | Erythromycin derivatives |
| JP3449766B2 (ja) | 1993-11-19 | 2003-09-22 | 中外製薬株式会社 | モチリンアンタゴニスト |
| US5767118A (en) * | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
| JP3901239B2 (ja) | 1996-03-13 | 2007-04-04 | 大正製薬株式会社 | アリールアルカン誘導体 |
| US5734012A (en) | 1996-05-16 | 1998-03-31 | Ohmeda Pharmaceutical Products Division Inc. | Cyclic motilin-like polypeptides with gastrointestinal motor stimulating activity |
| DE19644195A1 (de) | 1996-10-24 | 1998-04-30 | Solvay Pharm Gmbh | 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| AU4968997A (en) | 1996-11-26 | 1998-06-22 | Chugai Seiyaku Kabushiki Kaisha | 13-membered ring macrolide compounds, medicine containing the same, and process for producing the same |
| TWI242011B (en) * | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US5972939A (en) | 1997-10-28 | 1999-10-26 | Ortho-Mcneil Pharmaceutical, Inc. | Cyclopentene derivatives useful as antagonists of the motilin receptor |
| DE19805822B4 (de) | 1998-02-13 | 2009-02-05 | Solvay Pharmaceuticals Gmbh | 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6165985A (en) | 1998-02-13 | 2000-12-26 | Solvay Pharmaceuticals Gmbh | 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| AU2001247357A1 (en) | 2000-03-13 | 2001-09-24 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclobutene derivatives useful as antagonists of the motilin receptor |
| US6392040B2 (en) | 2000-03-13 | 2002-05-21 | Ortho-Mcneil Pharmaceutical, Inc. | Cyclopentene compounds useful as antagonists of the motilin receptor |
| AU2001250820A1 (en) | 2000-03-13 | 2001-09-24 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclohexene derivatives useful as antagonists of the motilin receptor |
| US6511980B2 (en) | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
| DE602004030344D1 (de) | 2003-07-31 | 2011-01-13 | Tranzyme Pharma Inc | Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen |
| WO2005012332A1 (en) | 2003-07-31 | 2005-02-10 | Tranzyme Pharma | Spatially-defined macrocycles incorporating peptide bond surrogates |
| US7338954B2 (en) | 2003-09-17 | 2008-03-04 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
| US7262195B2 (en) | 2003-09-17 | 2007-08-28 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
| WO2006011035A1 (en) | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
| NZ556627A (en) * | 2005-02-22 | 2010-09-30 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| US7582611B2 (en) | 2005-05-24 | 2009-09-01 | Pfizer Inc. | Motilide compounds |
| EP1902022A1 (en) | 2005-07-12 | 2008-03-26 | Glaxo Group Limited | Piperazine heteroaryl derivates as gpr38 agonists |
| MY150098A (en) | 2005-07-26 | 2013-11-29 | Glaxo Group Ltd | Benzylpiperazine derivates and their medical use |
| EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| PL2041093T3 (pl) * | 2006-06-28 | 2010-09-30 | Glaxo Group Ltd | Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38 |
-
2010
- 2010-03-01 EP EP10746028.9A patent/EP2401268B1/en active Active
- 2010-03-01 JP JP2011536661A patent/JP5663743B2/ja active Active
- 2010-03-01 CN CN201080007432.5A patent/CN102317280B/zh active Active
- 2010-03-01 RU RU2011139287/04A patent/RU2533116C2/ru active IP Right Revival
- 2010-03-01 MX MX2011008857A patent/MX2011008857A/es active IP Right Grant
- 2010-03-01 WO PCT/JP2010/001368 patent/WO2010098145A1/en not_active Ceased
- 2010-03-01 KR KR1020117021833A patent/KR101575703B1/ko active Active
- 2010-03-01 CA CA2750699A patent/CA2750699C/en not_active Expired - Fee Related
- 2010-03-01 ES ES10746028.9T patent/ES2547415T3/es active Active
- 2010-03-01 BR BRPI1007962A patent/BRPI1007962A2/pt not_active IP Right Cessation
- 2010-03-01 US US13/203,301 patent/US8697877B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004529184A (ja) | 2001-05-10 | 2004-09-24 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規１−アミドメチルカルボニル−ピペリジン誘導体、該誘導体を製造するための方法及び中間体並びにこれらの化合物を含有している医薬 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2401268A1 (en) | 2012-01-04 |
| US8697877B2 (en) | 2014-04-15 |
| CN102317280B (zh) | 2014-07-23 |
| JP5663743B2 (ja) | 2015-02-04 |
| CA2750699C (en) | 2015-12-29 |
| RU2533116C2 (ru) | 2014-11-20 |
| CN102317280A (zh) | 2012-01-11 |
| EP2401268B1 (en) | 2015-07-29 |
| EP2401268A4 (en) | 2013-01-02 |
| KR20110133033A (ko) | 2011-12-09 |
| MX2011008857A (es) | 2011-09-30 |
| BRPI1007962A2 (pt) | 2016-02-23 |
| WO2010098145A1 (en) | 2010-09-02 |
| HK1164318A1 (en) | 2012-09-21 |
| ES2547415T3 (es) | 2015-10-06 |
| RU2011139287A (ru) | 2013-04-10 |
| US20110312933A1 (en) | 2011-12-22 |
| JP2012519153A (ja) | 2012-08-23 |
| CA2750699A1 (en) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102164920B (zh) | 烷基噻唑氨基甲酸酯衍生物、其制备方法和其作为faah酶抑制剂的用途 | |
| WO2010087399A1 (ja) | ウロテンシンｉｉ受容体拮抗薬 | |
| ES2748402T3 (es) | Derivado de 2-acilaminotiazol y sal del mismo | |
| CA2565843A1 (en) | Novel compounds of proline and morpholine derivatives | |
| WO1999055674A1 (en) | 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds | |
| US20100105727A1 (en) | Novel benzamide derivatives and process for the prepartion thereof | |
| RU2396257C2 (ru) | Производные 4-аминопиперидина | |
| US20080096861A1 (en) | Chemical Compounds | |
| CA2961033A1 (en) | Heterocyclic compound | |
| WO2013147160A1 (ja) | 環状アミン誘導体及びその医薬用途 | |
| EP2580193A1 (en) | Benzamide derivatives and their use as hsp90 inhibtors | |
| JP5663743B2 (ja) | モチリン受容体作動活性を有するオキシインドール誘導体 | |
| ES2668873T3 (es) | Compuestos de indazol como agonistas del receptor 5-ht4 | |
| JP2012519153A5 (enExample) | ||
| US6645971B1 (en) | Quinazolinone derivatives | |
| EP3507287B1 (en) | Substituted n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives p2x7 receptor antagonists | |
| JP2013075894A (ja) | Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩からなる医薬 | |
| JPH111472A (ja) | ベンズアミド誘導体及びそれを含有する医薬組成物 | |
| HK1164318B (en) | Oxyindole derivatives with motilin receptor agonistic activity | |
| JP5665537B2 (ja) | ピラゾール３，５カルボキシレート誘導体、これらの調製および治療上の適用 | |
| AU2008297251A1 (en) | Piperidine derivatives as NK3 receptor antagonists | |
| ES2364254T3 (es) | Piperidinilcarbonil pirrolidinas y su uso como agonistas de melanocortina. | |
| JPWO2006080519A1 (ja) | ジアミン誘導体 | |
| JPWO2004074277A1 (ja) | Ｎ−アリール又はｎ−ヘテロアリールピペラジン誘導体及びそれを含有する医薬 | |
| JP2005325031A (ja) | １−シンナミルピペリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20110919 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20150225 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20150225 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150612 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20151008 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20151202 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20151202 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20181115 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181115 Start annual number: 4 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20211025 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20211025 Start annual number: 7 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241111 Start annual number: 10 End annual number: 12 |